Business UpdateJun 4, 2026, 09:06 AM
Autonomix Medical Discusses Visceral Cancer Pain Treatment
AI Summary
Autonomix Medical, Inc. announced its participation in a Virtual Investor "What This Means" segment, featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope. Dr. Kachaamy discussed the clinical significance of data presented at the Society of Surgical Oncology Annual Meeting, focusing on the company's approach to managing visceral cancer pain and its differentiation from existing treatments. The discussion also covered the broader applicability of the findings beyond pancreatic cancer and how the results support the ongoing clinical development and feasibility of Autonomix's technology platform.
Key Highlights
- Autonomix Medical participated in a Virtual Investor "What This Means" segment.
- Dr. Toufic Kachaamy discussed the clinical significance of data presented at the SSO Annual Meeting.
- The segment highlighted the importance of the work being selected for a podium presentation.
- It explored the potential clinical impact of the Company's approach to managing visceral cancer pain.
- Dr. Kachaamy addressed the broader applicability of findings beyond pancreatic cancer.
- The results support ongoing clinical development and feasibility of the technology platform.
- Autonomix's platform uses a catheter-based microchip sensing array for nerve-targeted treatments.
- Initial trials focus on pancreatic cancer pain, with potential for cardiology, hypertension, and chronic pain.
Price Impact
More from AMIX